Venetoclax Induces Rapid Elimination Of Npm1 Mutant Measurable Residual Disease In Combination With Low-Intensity Chemotherapy In Acute Myeloid Leukaemia
BRITISH JOURNAL OF HAEMATOLOGY(2021)
摘要
Based on promising results in older adults with acute myeloid leukaemia (AML), we treated patients with NPM1(mut) measurable residual disease (MRD) using off-label venetoclax in combination with low-dose cytarabine or azacitidine. Twelve consecutive patients were retrospectively identified, including five with molecular persistence and seven with molecular relapse/progression. All patients with molecular persistence achieved durable molecular complete remission (CRMRD-) without transplantation. Six of seven patients with molecular relapse/progression achieved CRMRD- after 1-2 cycles of venetoclax. This paper highlights the promising efficacy of venetoclax-based therapy to reduce the relapse risk in patients with persistent or rising NPM1(mut) MRD.
更多查看译文
关键词
AML, MRD, NPM1, venetoclax
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要